| |
FAQs
Select from the following:
FAQs- General
FAQs- Technology Transfer Center
(TTC)
FAQs - General
Who is Hovione?
Hovione is an international company dedicated to the manufacture of active
pharmaceutical ingredients (APIs), used for medicines for human diseases.
We serve the pharma industry exclusively, and specialize in the development
and synthesis of new APIs using state-of-the-art technology and quality.
Hovione was founded in Portugal in 1959 by Ivan Villax, and remains today
an independently owned company. Hovione has 2 FDA inspected plants in
Europe (Portugal) and the Far East (Macao) and a Technology Transfer Center
in New Jersey, USA. With sales of USD146m, the company exports all of its
production and technical services to a total of 28 countries worldwide.
What is Hovione´s activity?
The company manufactures generic drug active ingredients with processes
developed in-house, and offers custom synthesis of APIs and regulated
intermediates for oral, topical, inhalation and injectable grade products,
including sterile bulk.
With respect to generics, Hovione has 4 main lines of products: semi-synthetic
antibiotics, anti-inflammatory corticosteroids, and imaging agents used
in injectable formulations for X-ray visualization of organs, arteries
and veins, and anti-hyperlipidemics. In custom synthesis, Hovione develops
and manufactures "new generation" APIs on an exclusive basis
for its customers; these include anti-AIDS drugs, cancer therapies, Alzheimer´s
treatments, and other novel therapies currently under investigation.
Hovione’s capabilities include process chemistry, worldwide regulatory
affairs, and kilo to multi-ton manufacture of APIs under FDA to cGMP (current
Good Manufacturing Practices) standards. Being one of the largest investor
in the Portuguese pharmaceutical industry, Hovione has developed more
than 100 chemical processes and holds more than 400 patents worldwide.
What does Hovione sell?
Hovione sells:
• Active
Pharmaceutical Ingredients
• Technical
services, namely:
• Development,
optimization and industrialization of API chemical processes;
• Small
quantity APIs for clinical trials;
• Process
validation;
• Analytical
methods development;
• Worldwide
registration with health authorities.
• Particle
Design
• Formulation
Development
What are Hovione sales and main markets?
With worldwide yearly revenues of about US$146m, Hovione´s main
markets are North America, Europe and Japan.
Hovione supplies its products and technical services to both large pharmaceutical
multinationals, and to small or medium sized biotech or drug discovery
companies.
Where is Hovione present internationally?
•
Loures, Portugal – R&D center
and manufacturing
• Macau,
South China - Manufacturing plant
• New
Jersey, USA - Technology Transfer Center
• Lucerne,
Switzerland – Licensing Office
• Hong
Kong – Sales Office
Why did Hovione build a plant in Macao?
For its proximity to the People´s Republic of China which supplies
almost 80% of the raw materials that the company uses, allowing for a
competitive cost advantage. Built in 1987, this plant manufactures a third
of Hovione´s total production and exports to Japan, the European
Union, USA, Asia, Australia and New Zealand.
What are Hovione´s main differentiating
factors?
Hovione distinguishes itself by its technological capacity and expertise,
as well as by its superior customer service. Hovione's main asset consists
of its highly specialized know how and its dedication to R&D, in which
it invests annually 8% of its revenues.
How many people does Hovione employ?
Hovione employs 1100 professionals worldwide, of which more than 360 have
a university degree and 40 have PhDs. The average age is between 38 years.
Hovione employs more professionals in R&D and quality than it does
in production.
¬ back to top
FAQs - Technology Transfer Center
(TTC)
East Windsor, New Jersey
When and why did Hovione establish a presence in
the USA?
Hovione LLC was incorporated in the USA in April 2001, naming Dave Hoffman
President of US Operations. Since the USA is Hovione´s biggest market, the
company´s presence in New Jersey allows for a greater proximity to its US
customers offering them a better and more efficient service and technical
support. Hovione´s presence in the US consists of a Technology Transfer
Centre (TTC) in East Windsor, New Jersey.
Where is the TTC located and why?
The TTC is located on an 8 acre parcel of land just off exit 8 of the New
Jersey Turnpike, in East Windsor. East Windsor Township is an ideal location
for technology companies servicing the Pharmaceutical Industry due to its
proximity to 9 of the world´s major pharmaceutical companies. The township
also has an excellent professional community owing to its centralized
location between New York and Philadelphia.
When did the TTC started its operations?
Groundbreaking took place on October 8, 2001 and initial occupancy occurred
in August 2002. CUH2A, Inc. (Princeton, NJ), a world leader in the design
and engineering of laboratory facilities was appointed the architectural
engineering firm, and Engineered Technologies Corporation, (Providence, RI)
the equipment manufacturer for the TTC. Turner Construction Company of
Somerset, NJ managed the construction of the facility.
What does the TTC consist of?
The new TTC building has a total area of 26,000 sq.ft. The site consists of commercial offices as
well as development laboratories, a GMP pilot plant and a GMP Spray Dryer
for small scale preparation of novel APIs.
What is the TTC´s offer?
The TTC offers process development and scale up services, along with quality
control/assurance and regulatory support to the pharmaceutical industry. The
TTC can undertake the initial process development of new APIs and produce
small quantities for clinical trials as well as validate and produce small
volume commercial drug substances. The technical capability of the TTC
mimics that of Hovione’s fully commercial facilities located in Europe and
South China for seamless transition of the process to commercial scale
production. The TTC is fully integrated into Hovione’s global quality
network offering US customer’s real-time data and regulatory support for
on-going production in Europe and China.
How many people does the TTC employ?
The TTC employs a total of 49 people, including research, production and
supporting services.
What authorities will govern the TTC´s activities?
The TTC's activity is in compliance with FDA Regulations and Good
Manufacturing Practices, as well as ICH (International Committee for
Harmonization) Guidelines. The TTC was last inspected by the FDA in April
2011.
In terms of Safety and Environment, Hovione is a subscriber to the
International Chamber of Commerce Charter for Sustainable Development. The
facility is an OSHA VPP STAR worksite. The facility is run in accordance
with a Responsible Care Program, which includes having an open relationship
with the community. This includes the neighborhood, the fire department,
emergency medical personnel and the East Windsor Municipal Utility Authority.
The TTC follows Department of Transportations (DOT) regulations (49CFR)
implementing the Hazmat Security plan. The site is also under the New Jersey
Environmental Protection (NJDEP) regulations (40CFR) for air, water and
waste. The site has been successful inspected on a periodic basis.
How does the TTC address environmental concerns?
It is Hovione´s policy to responsibly address environmental as well as
safety issues in all areas - at the design project level of any construction,
at the R&D level of the API process development, and in its procedures and
professional attitude. Details of our Environment and Safety at Work policy
specific to the New Jersey site have been drawn up. No complaints have been
received from neighbors or Township officials concerning the operation of
the facility.
How does the TTC address air quality - atmospheric
emissions?
All the vent lines from the reactors in either the large scale-up laboratory
or pilot plant area are treated by use of a three stage control system. Each
reactor is equipped with a vent condenser operating at -37 F, which is
intended to remove any solvent contaminants from the exhaust. The exhaust
passes through a "scrubber" unit to further remove any remaining
contaminants from the exhaust stream and then prior to being exhausted
through the exhaust stack it is filtered through a carbon absorption filter,
which eliminates any remaining air born contaminants. The facility is
currently permitted and regularly monitored by the NJ Department of
Environmental Protection (NJDEP) for all air emissions from the site. No
visible emissions or odors have been detected or reported by neighbors or
Township officials.
How does the TTC address water quality - residual
waters?
All cooling water used within the facility is provided by internal closed
loop cooling system and is not interconnected to the municipal city water
lines.
All the firewater is collected in a firewater containment system. This is to
prevent contamination of the municipal treatment facility as well as the
surrounding grounds of the TTC. Firewater is collected in a holding tank and
is then sampled to determine if it is within the Township discharge limits.
Collected water within limits is discharged to the municipal authority.
Water which is not within discharge limits is collected by a licensed waste
contractor and sent to a permitted wastewater treatment facility.
Discharges of wastewater to the municipal authority are monitored
periodically by the Township to ensure all contaminants are within discharge
limits.
How does the TTC address Safety?
The site was approved for participation in the OSHA Voluntary Protection
Program (VPP) on 1 June 2007. Participation in this prestigious program is
limited to facilities which have accident and injury rates below their
industry average for at least three years and have a safety & health program
that exceeds the current regulatory standards. The TTC is free from
regulatory inspections by OSHA for a period of at least 3 years.
All chemical storage areas within the facility have separate spill
containment. All areas of the facility, which use larger than laboratory
quantities of products, are equipped with a foam suppression system. This is
a total deluge sprinkler system, which is specifically designed to
extinguish chemical related fires.
As part of our Responsible Care Program, the TTC has on record a copy of the
Material Safety Data Sheet for all the products used within the facility and
has provided a copy to the local fire and emergency response agencies for
their records.
The facility is on the leading edge of the determination of occupational
exposure limit estimations for new chemical entities and active
pharmaceutical ingredients (API). Estimations involve set formulas which
utilize known toxicological data and safety factors for human to animal
interpolations or differences in exposure route or bioavailability. If data
does not exist then a default categorization of "hazardous" is applied.
Based on the OEL estimate, the associated engineering controls and work
practices are implemented to ensure employee protection. Periodic air
monitoring is conducted to ensure employee exposures are below design levels.
Each project is thoroughly evaluated from an HSE perspective prior to being
accepted into the facility. A review is completed on all solvents and raw
materials to determine health or environmental risk. Very hazardous
chemicals are handled similar to the hazardous API with all associated
controls. Environmental impact is also assessed to include air or water
permit limitations as well as waste generation. Any chemicals which may not
be utilized at the facility within regulatory limits are required to have a
less hazardous substitute.
How does the TTC handle residual wastes?
All hazardous and chemical wastes are collected and transferred from the TTC
via a licensed waste contractor to a State Approved Treatment Facility. Any
wastes which contain API's or intermediates are treated by incineration.
Waste batteries and fluorescent lights are collected and sent for offsite
recycling by a licensed waste contractor. Cardboard, office paper, glass and
aluminum are collected and recycled by the Township.
The facility has a current Waste Minimization Program to try and reduce the
quantity and hazards of the wastes generated.
Updated: October 2011
For further information, please contact:
In the US:
Toll free: 866 918 2601
Hovione LLC
40 Lake Drive
East Windsor
NJ 08520
Tel: + 1 609 918 2600 - Fax: +1 609 918 2615
Email:
¬ back to
top |